HOME > Corporate Information > Corporate Profile

Corporate Profile

Company Name TRANS GENIC INC.
Established in 21 April, 1998
Main Business Development and distribution of genetically engineered animals and antibodies and licensing of these activities.
Research and development using genetically engineered animals and antibodies - discovery and identification of biomarker.
Nonclinical study using disease-animal model.
Gene analysis
Executives Representative Director
Director
Director
Director
Director
Audit & Supervisory Board Member
Audit & Supervisory Board Member
Audit & Supervisory Board Member
Kenji Fukunaga
Ken-ichi Yamamura
Shunichi Kitajima
Yutaka Funabashi
Tsutomu Seito
Noriaki Torisu
Takao Sato
Naoki Mitsuyasu
Capital 2,718 million yen (Mar. 31, 2017)
Gross Sales 2,302 million yen (Consolidated: fiscal year ended March 2017)
Accounting Term March 31
Employees 32 persons (Mar. 31, 2017)
137 persons (Consolidated: Mar. 31, 2017)
Average age of the employees is 40.5 years old
Corporate Auditor Deloitte Touche Tohmatsu Japan
Corporate Auditor Deloitte Tokyo Stock Exchange Mothers Section
Code: 2342
Consolidated Subsidiary New Drug Research Center, Inc.
Genetic Lab Co., Ltd.
Mediffom Inc.
Primmune Inc.
Equity-method Affiliate Medicinal Chemistry Pharmaceuticals, Co.,Ltd.
Back to Top

History

1998 Apr. Kumamoto Immunochemical Laboratories Inc. established after the reorganization of Kumamoto Immunochemical Laboratories 2000 Apr.tarted the gene knockout project
2000 Apr. Company name changed to TRANS GENIC INC.
2001 Dec. Concluded an agreement of sales for gene sequence of knockout mice with Yamanouchi Pharmaceutical Co., Ltd (Currently:Astellas Pharma Inc). Concluded an agreement of sales for gene sequence of knockout mice with Sumitomo Chemical Co., Ltd.
2002 Dec. Listed on TSE: Mothers
2003 Jul. Relocated Head Office to Mashiki-machi, Kamimashiki-gun, Kumamoto Pref.
2004 Mar. Established Immunokick Incorporation (Equity-method Affiliate)
2005 Jul. Established Kobe Research Center
2006 Feb.
May.
Relocated Head Office to Kumamoto City
Acquisition of Primmune Inc.
2010 Nov. Established Tokyo Office
2012 Dec. Relocated Head Office to Chuo-ku,Kumamoto City
2013 Apr.


Jul.
Established New Drug Research Center, Inc. (Consolidated Subsidiary)
New Drug Research Center, subsidiary of TRANS GENIC, to acquire business from New Drug Development Research Center Inc.
Acquisition of GeneticLab Co., LTD. (Consolidated Subsidiary)
Acquisition of Mediffom Inc.(Consolidated Subsidiary)
2015 Jul. Relocated Head Office to Chuo-ku, Fukuoka City
Back to Top

Address&Map

Fukuoka Head Office
■ Fukuoka Head Office
ibb Fukuoka 2F
2-3-36 Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka 810-0001 Japan
TEL : +81-92-288-8470
FAX : +81-92-288-8473
Map
Access
From Tenjin Station ······
  1 min. walk from Tenjin Station
From Fukuoka Station ······
  10 minutes by car
Back to Top
Kobe Research Center
■ Kobe Research Center
7-1-14 Minatojimaminami-machi, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan
TEL : +81-78-306-0590
FAX : +81-78-306-0589
Map
Access
From Kobe Airport ······
    10 minutes by car
    5 minutes walk from K Computer Mae Station (PORT LINER)
From Sannomiya Station ······
    15 minutes by car
    5 minutes walk from K Computer Mae Station (PORT LINER)
Back to Top
Tokyo Office
■ Tokyo Office
Yurakucho Denki Building South Tower 4F
1-7-1 Yurakucho, Chiyoda-ku, Tokyo 100-0006 Japan
TEL : +81-3-6551-2601
FAX : +81-3-6551-2602
Map
Access
From the Station ······
  1 minute walk from Yurakucho Station (JR Line)
  a direct connection with Yurakucho Station (A3 exits)(Tokyo Metro Yurakucho Line)
  a direct connection with Hibiya Station (A3 exits)(Tokyo Metro Chiyoda Line / Hibiya Line / Mita Line)
  • Press Releases
Contact us/Products & ServiceE-mail
  • Reproductive Technology Training
Back to Top